Janssen Pharmaceutica Nv

Centocor, Inc.

Immunex Corporation

Janssen Biotech, Inc.

Janssen Pharmaceuticals, Inc.

Dartmouth College

Centocor Ortho Biotech Inc.

Linda Snyder

Gordon Powers

Marco Gottardis

Rebecca Hawkins

Douglas H Yamada

Jill M Giles-Komar

Bernard Scallon

Mohit Trikha

Jay Rothstein

Jin Lu

Enrique Zudaire Ubani

Michael Molloy

Douglas Matthew Marvel

Marian T Nakada

Jill Carton

Thomas C Nesspor

Isabelle Lemercier

Manuel Alejandro Sepulveda

John D Alvarez

Deborah J Marshall

Dov Pechenick

Raymond W Sweet

George A Heavner

John Kehoe

Cam Holland

Daniel Villarreal

Joshua Goldstein

Allen Magill

Deepak Saini

Steve P Weng

Alejandro Sepulveda

Catherine Carriere

The present invention relates to antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of eliciting certain biological responses using the antibodies. Compositions and methods of using anti-VISTA antibodies in combination with one or more antibodies that bind to immune checkpoint proteins are also provided.

Anti-VISTA antibodies and fragments, uses thereof, and methods of identifying same

Disclosed are methods of treating prostate cancer by administering niraparib to a human in need thereof.

Methods of treating prostate cancer

The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of detecting VISTA.

Anti-VISTA antibodies and fragments

The invention provides agonistic anti-human VISTA antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.

Anti-human vista antibodies and use thereof

The present invention relates to antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of eliciting certain biological responses using the antibodies. Methods of identifying anti-VISTA antibodies capable of eliciting certain biological responses are also included.

Anti-vista antibodies and fragments, uses thereof, and methods of identifying same

The invention provides antagonistic and agonistic anti-human VISTA antibodies and antibody fragments. These antagonist antibodies and antibody fragments may be used to inhibit or block VISTA's suppressive effects on T cell immunity and thereby promote T cell immunity. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These antagonist antibodies and antibody fragments are especially useful in the treatment of cancer and infectious conditions. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.

Anti-human VISTA antibodies and use thereof

The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of making and using same. Methods of use include methods of treatment of cancer, including leukemias, lymphomas, solid tumors and melanomas.

Anti-vista antibodies and fragments

Method of treating prostate cancer

Growing community of inventors

Pottstown, PA, United States of America

Linda Snyder